Fa M, Bergström F, Hägglöf P, Wilczynska M, Johansson L B, Ny T
Department of Medical Biosciences, Medical Biochemistry, Umeâ University, Umeâ, S-90187, Sweden.
Structure. 2000 Apr 15;8(4):397-405. doi: 10.1016/s0969-2126(00)00121-0.
The inhibitors that belong to the serpin family are widely distributed regulatory molecules that include most protease inhibitors found in blood. It is generally thought that serpin inhibition involves reactive-centre cleavage, loop insertion and protease translocation, but different models of the serpin-protease complex have been proposed. In the absence of a spatial structure of a serpin-protease complex, a detailed understanding of serpin inhibition and the character of the virtually irreversible complex have remained controversial.
We used a recently developed method for making precise distance measurements, based on donor-donor energy migration (DDEM), to accurately triangulate the position of the protease urokinase-type plasminogen activator (uPA) in complex with the serpin plasminogen activator inhibitor type 1 (PAI-1). The distances from residue 344 (P3) in the reactive-centre loop of PAI-1 to residues 185, 266, 313 and 347 (P1') were determined. Modelling of the complex using this distance information unequivocally placed residue 344 in a position at the distal end from the initial docking site with the reactive-centre loop fully inserted into beta sheet A. To validate the model, seven single cysteine substitution mutants of PAI-1 were used to map sites of protease-inhibitor interaction by fluorescence depolarisation measurements of fluorophores attached to these residues and cross-linking using a sulphydryl-specific cross-linker.
The data clearly demonstrate that serpin inhibition involves reactive-centre cleavage followed by full-loop insertion whereby the covalently linked protease is translocated from one pole of the inhibitor to the opposite one.
属于丝氨酸蛋白酶抑制剂(serpin)家族的抑制剂是广泛分布的调节分子,包括血液中发现的大多数蛋白酶抑制剂。一般认为丝氨酸蛋白酶抑制剂的抑制作用涉及反应中心裂解、环插入和蛋白酶易位,但已提出了不同的丝氨酸蛋白酶抑制剂 - 蛋白酶复合物模型。在缺乏丝氨酸蛋白酶抑制剂 - 蛋白酶复合物空间结构的情况下,对丝氨酸蛋白酶抑制剂抑制作用以及几乎不可逆复合物特性的详细理解一直存在争议。
我们使用了一种基于供体 - 供体能量迁移(DDEM)的最近开发的精确距离测量方法,以准确三角测量与丝氨酸蛋白酶抑制剂1型(PAI - 1)复合的蛋白酶尿激酶型纤溶酶原激活剂(uPA)的位置。确定了从PAI - 1反应中心环中第344位残基(P3)到第185、266、313和347位残基(P1')的距离。使用此距离信息对复合物进行建模明确将第344位残基置于远离初始对接位点的远端位置,反应中心环完全插入β折叠A中。为了验证该模型,使用PAI - 1的七个单半胱氨酸取代突变体通过对连接到这些残基的荧光团进行荧光去极化测量以及使用巯基特异性交联剂进行交联来绘制蛋白酶 - 抑制剂相互作用位点图。
数据清楚地表明,丝氨酸蛋白酶抑制剂的抑制作用涉及反应中心裂解,随后是环的完全插入,由此共价连接的蛋白酶从抑制剂的一极转移到另一极。